EP2012824A4 - Uses and compositions for treatment of psoriasis - Google Patents

Uses and compositions for treatment of psoriasis

Info

Publication number
EP2012824A4
EP2012824A4 EP07755413A EP07755413A EP2012824A4 EP 2012824 A4 EP2012824 A4 EP 2012824A4 EP 07755413 A EP07755413 A EP 07755413A EP 07755413 A EP07755413 A EP 07755413A EP 2012824 A4 EP2012824 A4 EP 2012824A4
Authority
EP
European Patent Office
Prior art keywords
psoriasis
compositions
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP07755413A
Other languages
German (de)
French (fr)
Other versions
EP2012824A2 (en
Inventor
Mary Kaye Willian
Martin M Okun
Rebecca S Hoffman
Yihua Gu
Anne Camez
Lisa E Melilli
Kenneth B Gordon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Biotechnology Ltd
Original Assignee
Abbott Biotech Ltd Bermuda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Biotech Ltd Bermuda filed Critical Abbott Biotech Ltd Bermuda
Priority to EP13172506.1A priority Critical patent/EP2666478A3/en
Publication of EP2012824A2 publication Critical patent/EP2012824A2/en
Publication of EP2012824A4 publication Critical patent/EP2012824A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
EP07755413A 2006-04-10 2007-04-10 Uses and compositions for treatment of psoriasis Ceased EP2012824A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13172506.1A EP2666478A3 (en) 2006-04-10 2007-04-10 Uses and compositions for treatment of psoriasis

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US79090906P 2006-04-10 2006-04-10
US80977006P 2006-05-30 2006-05-30
US81548906P 2006-06-20 2006-06-20
US81789106P 2006-06-29 2006-06-29
US84012206P 2006-08-25 2006-08-25
US89926207P 2007-02-02 2007-02-02
US90968307P 2007-04-02 2007-04-02
PCT/US2007/009131 WO2007120823A2 (en) 2006-04-10 2007-04-10 Uses and compositions for treatment of psoriasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP13172506.1A Division EP2666478A3 (en) 2006-04-10 2007-04-10 Uses and compositions for treatment of psoriasis

Publications (2)

Publication Number Publication Date
EP2012824A2 EP2012824A2 (en) 2009-01-14
EP2012824A4 true EP2012824A4 (en) 2010-06-16

Family

ID=38610206

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07755413A Ceased EP2012824A4 (en) 2006-04-10 2007-04-10 Uses and compositions for treatment of psoriasis

Country Status (2)

Country Link
EP (1) EP2012824A4 (en)
WO (1) WO2007120823A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110452A2 (en) * 2004-04-09 2005-11-24 Abbott Biotechnology Ltd. MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFα-RELATED DISORDERS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219142A1 (en) * 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110452A2 (en) * 2004-04-09 2005-11-24 Abbott Biotechnology Ltd. MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFα-RELATED DISORDERS

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Adalimumab efficacy and safety results in patients with moderate to severe chronic plaque psoriasis with and without psoriatic arthritis", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, C.V. MOSBY, ST. LOUIS, MO, US, vol. 52, no. 3, 1 March 2005 (2005-03-01), pages P174, XP004840889, ISSN: 0190-9622 *
"Long-term safety and efficayc of adalimumab in the treatment of moderate to severe chronic plaque psoriasis", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, C.V. MOSBY, ST. LOUIS, MO, US, vol. 52, no. 3, 1 March 2005 (2005-03-01), pages P8, XP002720516, ISSN: 0190-9622 *
CHEN DM ET AL.: "ADALIMUMAB EFFICACY AND SAFETY IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: PRELIMINARY FINDINGS FROM A 12-WEEK DOSE-RANGING TRIAL", SUPPLEMENT TO THE JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. 50, no. 3, P2, March 2004 (2004-03-01), pages P1, XP002580561 *
CHEW A-L ET AL: "Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab.", THE BRITISH JOURNAL OF DERMATOLOGY AUG 2004 LNKD- PUBMED:15327561, vol. 151, no. 2, August 2004 (2004-08-01), pages 492 - 496, XP002580563, ISSN: 0007-0963 *
GORDON KENNETH B ET AL: "Definitions of measures of effect duration for psoriasis treatments.", ARCHIVES OF DERMATOLOGY JAN 2005 LNKD- PUBMED:15655149, vol. 141, no. 1, January 2005 (2005-01-01), pages 82 - 84, XP009132702, ISSN: 0003-987X *
KOO J ET AL: "Update on the mechanisms and efficacy of biological therapies for psoriasis", JOURNAL OF DERMATOLOGICAL SCIENCE, ELSEVIER SCIENCE PUBLISHERS, SHANNON, IR LNKD- DOI:10.1016/J.JDERMSCI.2005.01.011, vol. 38, no. 2, 1 May 2005 (2005-05-01), pages 75 - 87, XP025305570, ISSN: 0923-1811, [retrieved on 20050501] *
PATEL TORAL ET AL: "Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis", DERMATOLOGIC THERAPY, MUNKSGAARD, COPENHAGEN, DK LNKD- DOI:10.1111/J.1396-0296.2004.04045.X, vol. 17, no. 5, 1 January 2004 (2004-01-01), pages 427 - 431, XP002477489, ISSN: 1396-0296 *
SAINI RITU ET AL: "Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.", CURRENT PHARMACEUTICAL DESIGN 2005 LNKD- PUBMED:15638763, vol. 11, no. 2, 2005, pages 273 - 280, XP009132703, ISSN: 1381-6128 *
SLADDEN M J ET AL: "Extensive plaque psoriasis successfully treated with adalimumab (Humira).", THE BRITISH JOURNAL OF DERMATOLOGY MAY 2005 LNKD- PUBMED:15888191, vol. 152, no. 5, May 2005 (2005-05-01), pages 1091 - 1092, XP002580562, ISSN: 0007-0963 *
WINTERFIELD L S ET AL: "Psoriasis treatment: current and emerging directed therapies.", ANNALS OF THE RHEUMATIC DISEASES MAR 2005 LNKD- PUBMED:15708946, vol. 64 Suppl 2, March 2005 (2005-03-01), pages II87 - II90 ; DI, XP002580559, ISSN: 0003-4967 *

Also Published As

Publication number Publication date
WO2007120823A2 (en) 2007-10-25
EP2012824A2 (en) 2009-01-14
WO2007120823A3 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
IL258730A (en) Compositions and methods for treatment of microbial disorders
EP2007426A4 (en) Uses and compositions for treatment of psoriatic arthritis
EP2361089A4 (en) Compositions and methods for the treatment of altered -synuclein function
HK1172326A1 (en) Compounds and compositions and methods of use
HK1134679A1 (en) Compositions and methods for the treatment of infections
EP1996612A4 (en) Compositions for treatment of cancer
IL202573A0 (en) Methods and compositions for treating allergic diseases
HK1159498A1 (en) Methods and compositions for the treatment of cancer
IL210810A0 (en) Compositions for the treatment of pain and/or inflamtion
IL243294A0 (en) Compounds and compositions for treatment of cancer
EP2049151A4 (en) Methods and compositions for the treatment of cancer
IL196843A0 (en) Compositions and methods for the treatment of radiation proctosigmoitis
IL210997A0 (en) Compositions for the treatment of mrsa and uses thereof
GB0718446D0 (en) Compositions and methods for the treatment of infection
EP2340027A4 (en) Methods and compositions for the treatment of cancer
IL209336A0 (en) Compositions for treating hyperproliferative diseases and uses thereof
IL198723A0 (en) Methods and compositions for therapeutic treatment
EP2176406A4 (en) Compositions and methods of treating cancer
EP2021005A4 (en) Methods and composition for treatment of inflammatory pain
GB0909297D0 (en) Composition for the treatment of skin conditions
EP2150270A4 (en) Methods and compositions for the treatment of cancer
GB0601950D0 (en) Compositions and methods of treating diabetes
EP2096927A4 (en) Therapeutic compositions and methods of treatment with capsianoside-type compounds
EP2285398A4 (en) Methods and compositions for the treatment of obesity
GB0504657D0 (en) Compositions and methods of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081110

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1126672

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20100520

17Q First examination report despatched

Effective date: 20110609

RAX Requested extension states of the european patent have changed

Extension state: HR

Payment date: 20081110

Extension state: BA

Payment date: 20081110

Extension state: RS

Payment date: 20081110

Extension state: MK

Payment date: 20081110

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABBVIE BIOTECHNOLOGY LTD

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20141213

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1126672

Country of ref document: HK